Kiniksa Pharmaceuticals International (KNSA) Free Cash Flow (2017 - 2026)

Kiniksa Pharmaceuticals International's Free Cash Flow history runs 10 years deep, the most recent figure standing at $50.1 million for Q1 2026.

• Quarterly Free Cash Flow rose 124.72% year-over-year to $50.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $164.6 million (up 378.99% YoY) and the FY2025 annual result came in at $136.8 million, up 757.31% from the prior year.
• Free Cash Flow was $50.1 million for Q1 2026 at Kiniksa Pharmaceuticals International, down from $53.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $62.0 million in Q3 2022 and bottomed at -$34.1 million in Q1 2022.
• A 5-year average of $13.3 million and a median of $9.0 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2024 — Free Cash Flow sank 113.31% — and 2025, when it surged 1461.97%.
• Kiniksa Pharmaceuticals International's Free Cash Flow stood at -$11.5 million in 2022, then soared by 177.82% to $9.0 million in 2023, then increased by 2.82% to $9.2 million in 2024, then surged by 480.54% to $53.6 million in 2025, then declined by 6.58% to $50.1 million in 2026.
• Business Quant data shows KNSA's Free Cash Flow at $50.1 million in Q1 2026, $53.6 million in Q4 2025, and $30.8 million in Q3 2025.